%PDF-1.4
%
124 0 obj
<>
endobj
121 0 obj
<>
endobj
190 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-10-07T08:54:41Z
2024-03-28T05:13:54-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T05:13:54-07:00
application/pdf
Heather
2002-1031.nov
uuid:059a7b35-1dd2-11b2-0a00-160a27edca00
uuid:059a7b37-1dd2-11b2-0a00-380000000000
endstream
endobj
110 0 obj
<>
endobj
111 0 obj
<>
endobj
125 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 90 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 92 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 94 0 R/Type/Page>>
endobj
27 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 96 0 R/Type/Page>>
endobj
50 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 98 0 R/Type/Page>>
endobj
73 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 100 0 R/Type/Page>>
endobj
76 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 102 0 R/Type/Page>>
endobj
79 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 104 0 R/Type/Page>>
endobj
221 0 obj
[225 0 R]
endobj
222 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 73.2 714.5293 Tm
(Res Cardiol 1997;92:17-24.)Tj
-1.95 -1.25 Td
[(25.)-550.1 (Ferrante )54.8 (A, Rowan-Kelly B, Seow )17.7 (WK, )17.7 (Thong )36.8 (YH. Depression of)]TJ
1.95 -1.25 Td
(human polymorphonuclear leucocyte function by anti-malarial)Tj
0 -1.25 TD
(drugs. Immunology 1986;58:125-30.)Tj
-1.95 -1.25 Td
[(26.)-550.1 (Mikes PS, Polomski LL, Gee JB. Mepacrine impairs neutrophil)]TJ
1.95 -1.25 Td
[(response after acute lung injury in rats. Ef)17.7 (fects on neutrophil )]TJ
T*
[(migration. )54.8 (Am Rev Respir Dis 1988;138:1464-70.)]TJ
-1.95 -1.25 Td
[(27.)-550.1 (Al Khader )54.8 (A, )54.8 (Al Sulaiman M, Kishore PN, Morais C, )17.7 (T)69.9 (ariq M.)]TJ
1.95 -1.25 Td
(Quinacrine attenuates cyclosporine-induced nephrotoxicity in rats.)Tj
T*
[(T)35 (ransplantation 1996;62:427-35.)]TJ
-1.95 -1.25 Td
[(28.)-550.1 (Authi KS, )17.7 (T)35 (raynor JR. Stimulation of polymorphonuclear leucocyte)]TJ
-0.0298 Tw 1.95 -1.25 Td
(phospholipase A)Tj
0 Tc 0 Tw 5.2 0 0 5.2 126.5055 601.8893 Tm
(2)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 131.3055 604.5293 Tm
(activity by chloroquine and mepacrine. J Pharm)Tj
-7.2632 -1.25 Td
(Pharmacol 1982;34:736-8.)Tj
-1.95 -1.25 Td
[(29.)-550.1 (W)79.9 (allace DJ. Is there a role for quinacrine \(atabrine\) in the new)]TJ
1.95 -1.25 Td
(millennium? Lupus 2000;9:81-2.)Tj
-1.95 -1.25 Td
[(30.)-550.1 (W)79.9 (allace DJ. )17.7 (The use of quinacrine \(atabrine\) in rheumatic diseases:)]TJ
1.95 -1.25 Td
[(a reexamination. Semin )54.8 (Arthritis Rheum 1989;18:282-96.)]TJ
-1.95 -1.25 Td
[(31.)-550.1 (D\325Cruz D. )54.8 (Antimalarial therapy: a panacea for mild lupus? Lupus)]TJ
0 Tc 0 Tw 1.95 -1.25 Td
(2001;10:148-51.)Tj
-0.00011 Tc 0.02499 Tw -1.95 -1.25 Td
[(32.)-550.1 (Chung HS, Hann SK. Lupus panniculitis treated by a combination)]TJ
1.95 -1.25 Td
(therapy of hydroxychloroquine and quinacrine. J Dermatol)Tj
0 Tc 0 Tw T*
(1997;24:569-72.)Tj
-0.00011 Tc 0.02499 Tw -1.95 -1.25 Td
[(33.)-550.1 (Lipsker D, Piette JC, Cacoub P)110.7 (, Godeau P)110.7 (, Frances C. )]TJ
1.95 -1.25 Td
(Chloroquine-quinacrine association in resistant cutaneous lupus.)Tj
T*
(Dermatology 1995;190:257-8.)Tj
-1.95 -1.25 Td
[(34.)-550.1 (T)69.9 (oubi E, Rosner I, Rozenbaum M, Kessel )54.8 (A, Golan )17.7 (TD. )17.7 (The benefit)]TJ
1.95 -1.25 Td
(of combining hydroxychloroquine with quinacrine in the treatment)Tj
T*
(of SLE patients. Lupus 2000;9:92-5.)Tj
-1.95 -1.25 Td
[(35.)-550.1 (Matucci-Cerinic M, Marabini S, Jantsch S, Cagnoni M, Partsch G.)]TJ
1.95 -1.25 Td
[(Ef)17.7 (fects of capsaicin on the metabolism of rheumatoid arthritis)]TJ
0 Tc T*
[(synoviocytes in vitro. )54.8 (Ann Rheum Dis 1990;49:598-602.)]TJ
-0.00011 Tc -1.95 -1.25 Td
[(36.)-550.1 (Ozols J. )54.8 (Amino acid analysis. Methods Enzymol 1990;182:587-601.)]TJ
T*
[(37.)-550.1 (Dyer RB, Herzog NK. Isolation of intact nuclei for nuclear extract)]TJ
1.95 -1.25 Td
(preparation from a fragile B-lymphocyte cell line. Biotechniques)Tj
0 Tc 0 Tw T*
(1995;19:192-5.)Tj
-0.00011 Tc 0.02499 Tw -1.95 -1.25 Td
[(38.)-550.1 (Konttinen )36.8 (YT)73.9 (, )54.8 (Ainola M, )17.7 (V)110.8 (alleala H, et al. )54.8 (Analysis of 16 dif)17.7 (ferent)]TJ
1.95 -1.25 Td
(matrix metalloproteinases \(MMP-1 to MMP-20\) in the synovial)Tj
T*
[(membrane: dif)17.7 (ferent profiles in trauma and rheumatoid arthritis.)]TJ
0 Tc T*
(Ann Rheum Dis 1999;58:691-7.)Tj
-0.00011 Tc -1.95 -1.25 Td
[(39.)-550.1 (V)59.8 (incenti MP)110.7 (, )17.7 (White LA, Schroen DJ, Benbow U, Brinckerhof)17.7 (f CE.)]TJ
1.95 -1.25 Td
(Regulating expression of the gene for matrix metalloproteinase-1)Tj
T*
[(\(collagenase\): mechanisms that control enzyme activity)64.8 (, )]TJ
T*
[(transcription, and mRNA)-220.2 (stability)64.9 (. Crit Rev Eukaryot Gene Expr)]TJ
0 Tc 0 Tw T*
[(1996;6:391-41)36.9 (1.)]TJ
-0.00011 Tc 0.02499 Tw -1.95 -1.25 Td
[(40.)-550.1 (Stuhlmeier KM, Csizmadia )17.7 (V)128.9 (,)-0.1 ( Cheng Q, )17.7 (W)39.9 (inkler H, Bach FH.)]TJ
1.95 -1.25 Td
[(Selective inhibition of E-selectin, ICAM-1 and )17.7 (VCAM in )]TJ
T*
(endothelial cells. Eur J Immunol 1994;24:2186-90.)Tj
-1.95 -1.25 Td
[(41.)-550.1 (McCawley LJ, Matrisian LM. Matrix metalloproteinases: they\325re not)]TJ
1.95 -1.25 Td
(just for matrix anymore! Curr Opin Cell Biol 2001;13:534-40.)Tj
-1.95 -1.25 Td
[(42.)-550.1 (Chang C, )17.7 (W)79.9 (erb Z. )17.7 (The many faces of metalloproteases: cell growth,)]TJ
1.95 -1.25 Td
[(invasion, angiogenesis and metastasis. )17.7 (T)35 (rends Cell Biol)]TJ
0 Tw T*
[(2001;1)36.8 (1:S37-43.)]TJ
0.02499 Tw -1.95 -1.25 Td
[(43.)-550.1 (Johnson LL, Dyer R, Hupe DJ. Matrix metalloproteinases. Curr)]TJ
1.95 -1.25 Td
(Opin Chem Biol 1998;2:466-71.)Tj
-1.95 -1.25 Td
[(44.)-550.1 (Stuhlmeier KM. Ef)17.7 (fects of quinacrine on endothelial cell)]TJ
1.95 -1.25 Td
[(morphology and transcription factor\320DNA)-220.2 (interactions. Biochim)]TJ
-0.0298 Tw T*
[(Biophys Acta )-54.8 (2001;1524:57-65.)]TJ
0.02499 Tw -1.95 -1.25 Td
[(45.)-550.1 (Shaulian E, Karin M. )54.8 (AP-1 in cell proliferation and survival.)]TJ
0 Tc 1.95 -1.25 Td
(Oncogene 2001;20:2390-400.)Tj
-0.00011 Tc -1.95 -1.25 Td
[(46.)-550.1 (Halazonetis )17.7 (TD, Geor)17.7 (gopoulos K, Greenber)17.7 (g ME, Leder P)110.7 (. c-Jun)]TJ
1.95 -1.25 Td
[(dimerizes with itself and with c-Fos, forming complexes of dif)17.7 (ferent)]TJ
T*
[(DNA)-220.1 (binding af)17.7 (finities. Cell 1988;55:917-24.)]TJ
31.05 76.25 Td
[(47.)-550.1 (Bakiri L, Lallemand D, Bossy-W)79.8 (etzel E, )36.8 (Y)99.8 (aniv M. Cell )]TJ
1.95 -1.25 Td
(cycle-dependent variations in c-Jun and JunB phosphorylation: a)Tj
T*
(role in the control of cyclin D1 expression. EMBO J )Tj
0 Tc 0 Tw T*
(2000;19:2056-68.)Tj
-0.00011 Tc 0.02499 Tw -1.95 -1.25 Td
[(48.)-550.1 (Bakiri L, Matsuo K, )17.7 (W)39.9 (isniewska M, )17.7 (W)79.9 (agner EF)79.7 (, )36.8 (Y)99.8 (aniv M. Promoter)]TJ
1.95 -1.25 Td
[(specificity and biological activity of tethered )54.8 (AP-1 dimers. Mol Cell)]TJ
0 Tc T*
(Biol 2002;22:4952-64.)Tj
-0.00011 Tc -1.95 -1.25 Td
[(49.)-550.1 (W)39.9 (isdom R, Johnson RS, Moore C. c-Jun regulates cell cycle)]TJ
1.95 -1.25 Td
(progression and apoptosis by distinct mechanisms. EMBO J)Tj
0 Tc 0 Tw T*
(1999;18:188-97.)Tj
-0.00011 Tc 0.02499 Tw -1.95 -1.25 Td
[(50.)-550.1 (Rutber)17.7 (g SE, Saez E, Lo S, et al. Opposing activities of c-Fos and)]TJ
1.95 -1.25 Td
[(Fra-2 on )54.8 (AP-1 regulated transcriptional activity in mouse)]TJ
T*
[(keratinocytes induced to dif)17.7 (ferentiate by calcium and phorbol esters.)]TJ
0 Tc T*
(Oncogene 1997;15:1337-46.)Tj
-0.00011 Tc -1.95 -1.25 Td
[(51.)-550.1 (Shemshedini L, Knauthe R, Sassone-Corsi P)110.8 (,)-0.1 ( Pornon )54.8 (A, Gronemeyer)]TJ
1.95 -1.25 Td
[(H. Cell-specific inhibitory and stimulatory ef)17.7 (fects of Fos and Jun on)]TJ
T*
(transcription activation by nuclear receptors. EMBO J)Tj
0 Tc 0 Tw T*
(1991;10:3839-49.)Tj
-0.00011 Tc 0.02499 Tw -1.95 -1.25 Td
[(52.)-550.1 (Bondeson J, Sundler R. )54.8 (Antimalarial drugs inhibit phospholipase )54.8 (A)]TJ
0 Tc 0 Tw 5.2 0 0 5.2 552.6841 531.8893 Tm
(2)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 337.2 524.5293 Tm
(activation and induction of interleukin 1 beta and tumor necrosis)Tj
T*
(factor alpha in macrophages: implications for their mode of action)Tj
T*
(in rheumatoid arthritis. Gen Pharmacol 1998;30:357-66.)Tj
-1.95 -1.25 Td
[(53.)-550.1 (W)79.9 (eber SM, Levitz SM. Chloroquine interferes with )]TJ
1.95 -1.25 Td
[(lipopolysaccharide-induced )17.7 (TNF-alpha gene expression by a)]TJ
T*
(nonlysosomotropic mechanism. J Immunol 2000;165:1534-40.)Tj
-1.95 -1.25 Td
[(54.)-550.1 (Jeong JY)128.8 (, Jue DM. Chloroquine inhibits processing of tumor)]TJ
1.95 -1.25 Td
[(necrosis factor in lipopolysaccharide-stimulated RA)79.7 (W)-257.1 (264.7)]TJ
T*
(macrophages. J Immunol 1997;158:4901-7.)Tj
-1.95 -1.25 Td
[(55.)-550.1 (Scaria PV)128.8 (, Craig JC, Shafer RH. Dif)17.7 (ferential binding of the)]TJ
1.95 -1.25 Td
(enantiomers of chloroquine and quinacrine to polynucleotides:)Tj
T*
(implications for stereoselective metabolism. Biopolymers)Tj
0 Tc 0 Tw T*
(1993;33:887-95.)Tj
-0.00011 Tc 0.02499 Tw -1.95 -1.25 Td
[(56.)-550.1 (Rivas L, Murza )54.8 (A, Sanchez-Cortes S, Garcia-Ramos JV)128.8 (. Interaction)]TJ
1.95 -1.25 Td
(of antimalarial drug quinacrine with nucleic acids of variable)Tj
T*
(sequence studied by spectroscopic methods. J Biomol Struct Dyn)Tj
0 Tc 0 Tw T*
(2000;18:371-83.)Tj
-0.00011 Tc 0.02499 Tw -1.95 -1.25 Td
[(57.)-550.1 (Jerushalmy Z, Englender )17.7 (T)74 (, Shaklai M. Phorbol-myristate-acetate-)]TJ
1.95 -1.25 Td
[(induced platelet aggregation in the presence of inhibitors. )54.8 (Acta)]TJ
T*
(Haematol 1988;80:210-5.)Tj
-1.95 -1.25 Td
[(58.)-550.1 (Shen CY)128.8 (, )17.7 (W)79.9 (ang D, Chang ML, Hsu K. Protective ef)17.7 (fect of)]TJ
1.95 -1.25 Td
(mepacrine on hypoxia-reoxygenation-induced acute lung injury in)Tj
0 Tc T*
[(rats. J )54.8 (Appl Physiol 1995;78:225-31.)]TJ
-0.00011 Tc -1.95 -1.25 Td
[(59.)-550.1 (Authi KS, )17.7 (T)35 (raynor JR. Stimulation of polymorphonuclear leucocyte)]TJ
-0.0298 Tw 1.95 -1.25 Td
(phospholipase A)Tj
0 Tc 0 Tw 5.2 0 0 5.2 390.5055 281.8893 Tm
(2)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 395.3055 284.5293 Tm
(activity by chloroquine and mepacrine. J Pharm)Tj
-7.2632 -1.25 Td
(Pharmacol 1982;34:736-8.)Tj
-1.95 -1.25 Td
[(60.)-550.1 (Cussac D, Schaak S, Denis C, Paris H. )54.8 (Alpha 2B-adrener)17.7 (gic)]TJ
1.95 -1.25 Td
(receptor activates MAPK via a pathway involving arachidonic acid)Tj
T*
(metabolism, matrix metalloproteinases, and epidermal growth factor)Tj
T*
(receptor transactivation. J Biol Chem 2002;277:19882-8.)Tj
-1.95 -1.25 Td
[(61.)-550.1 (von Schmiedeber)17.7 (g S, Ronnau )54.8 (AC, Schuppe HC, Specker C, Ruzicka)]TJ
1.95 -1.25 Td
[(T)74 (, Lehmann P)110.7 (. Combination of antimalarial drugs mepacrine and)]TJ
T*
(chloroquine in therapy refractory cutaneous lupus erythematosus.)Tj
T*
(Hautarzt 2000;51:82-5.)Tj
-1.95 -1.25 Td
[(62.)-550.1 (Keyszer G, Lambiri I, Nagel R, et al. Circulating levels of matrix)]TJ
1.95 -1.25 Td
(metalloproteinases MMP-3 and MMP-1, tissue inhibitor of )Tj
T*
(metalloproteinases 1 \(TIMP-1\), and MMP-1/TIMP-1 complex in)Tj
T*
(rheumatic disease. Correlation with clinical activity of rheumatoid)Tj
T*
(arthritis versus other surrogate markers. J Rheumatol )Tj
0 Tc 0 Tw T*
(1999;26:251-8.)Tj
-0.00011 Tc 0.02499 Tw -1.95 -1.25 Td
[(63.)-550.1 (Nakamura )17.7 (T)74 (, Ebihara I, )17.7 (T)69.9 (omino )36.8 (Y)128.9 (, Koide H. Ef)17.7 (fect of a specific)]TJ
1.95 -1.25 Td
[(endothelin )54.8 (A)-220.1 (receptor antagonist on murine lupus nephritis. Kidney)]TJ
T*
(Int 1995;47:481-9.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_1 1 Tf
8 0 0 8 54.5 35.9844 Tm
(Stuhlmeier: Mepacrine inhibits MMP-1 and MMP-9)Tj
0 Tc 0 Tw 60.9375 -0.0313 Td
(2337)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_2 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
104 0 obj
<>stream
8;Z\6$ZbPe#itt$j>rjMg(1K"/(:GfG/A$%-P8hP/;l;Kp9?hoOn&3lg?:MVj/6BV
qj\ng_[HKu4o0Dj:3cthrZ7DeUXA,t-W9u/H+U(>5:N;Fabqoa%_t7Q5/(A"@0T`Fejj+,@cfWBG`=9P%>DE
ID-jc@qT4gJEc&b?A,tX0?jP9cgG^08a!Vrh)&Nj#=1mJj]k$`U8p5EJA$aB&fBbB
HN?`?-'m%N;n!_/g1N,J?JQJVp`/T@=a%hu@,N@hiF5%Z]Ln*7=\g[CmnI[.H*mr+M2=\1.$rF+G,%B?H[WuL=!6Y6ALK>ho]1*YH
EJSNKblJ(m.mrbF/T%T>fM\H)&Q"s-a"98]7oegFqgiCVALr7-^n1`,PZJHDE34/G
64QC2MQ#)t&KH,[/P/$]ZigW56UoDa&XD'FYSqroq\8:c$a/sPT+p0=SblfRfSqlr
MLYefF!ROX2"/Bf'qQpAbr-N]*apG_1_id";g=0=h.MUt.]if0nM(P%i+640?;j5p
CAZW6b@HS"YN,V;T*0A-U#@n^TsC-1nk;ZKZt8X(Na#J8H"neK5ls/>[OV*H%j\$1
>c!\l*g/87lTHT6FIj5k\2-S,M*a;]9mXTOXUT$Q/Wj1frZY:Dj*9+6I1!C!HQp;R
S^ZR]7Kk'G_M`-1a_K[IFJ&a&@9F(g?7S$:pnpHYj=gT=_r&VM?e40<5kS/I#=3
<>qpa50FW3Z/
endstream
endobj
108 0 obj
[/Indexed/DeviceRGB 255 107 0 R]
endobj
107 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
132 0 obj
<>
endobj
127 0 obj
<>
endobj
163 0 obj
<>
endobj
195 0 obj
<>
endobj
128 0 obj
<>
endobj
155 0 obj
<>stream
HiPSYB@$y"zoJ@*ƈy\ޙDB'0D?ܘZ,%ӂ/ ~@,I;1)BoNJ!'e
3űG&17lyاX`
l{-p>j`6'<^qkKYM"MأM/LgvI̒)sOۗ*xrf,M-+X}ozf
lm/,Ǘ.aϮ+%4成9?I JvϡeSl_
8g452 ['ǿ #үAx*JY++G境Č|Ivy]N
Q7͡t1CK.vKͲl$ V#='e&ge9JvQNLAW8tBi!š>JI4.]#9TzL H{R(gr)z;h'pc/NTDRVeg6
lZuڷ+Z1ĿS0vc`<n`ݝIMMԸYEN)B57k